Abstract |
Bone is the most common site of metastases from breast and prostate cancer, and bone destruction is characteristic of multiple myeloma. Increased osteoclast activity plays a key role in cancer-induced bone destruction. Bisphosphonates reduce osteoclastic bone resorption through various mechanisms as yet not fully elucidated. Bisphosphonates have proven to be effective in the treatment of tumor-induced hypercalcaemia. Several clinical trials indicated that these compounds can positively influence many aspects of neoplastic bone disease, however, many questions regarding their long-term efficacy and optimal therapeutic schedule await clarification from well-designed clinical trials.
|
Authors | G Merlini, I Turesson |
Journal | Medical oncology (Northwood, London, England)
(Med Oncol)
Vol. 13
Issue 4
Pg. 215-21
(Dec 1996)
ISSN: 1357-0560 [Print] United States |
PMID | 9152972
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antineoplastic Agents
- Diphosphonates
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Bone Neoplasms
(complications, drug therapy, secondary)
- Breast Neoplasms
(pathology)
- Diphosphonates
(pharmacology, therapeutic use)
- Female
- Humans
- Hypercalcemia
(drug therapy, etiology)
- Male
- Multiple Myeloma
(pathology)
- Prostatic Neoplasms
(pathology)
|